Case Report

Camrelizumab-Induced Isolate Abducens Neuritis: A Rare Ophthalmic Immune-Related Adverse Events

Yanli Hou 1, Qiang Su 2, Simeng Tang 1 and Hongyang Li 1,*

1 Department of Ophthalmology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China
2 Department of Oncology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China
* Correspondence: faraway_sweet@163.com; Tel.: +86-010-6313-9094

Abstract: Background: Anti-tumor immunotherapy with immune checkpoint inhibitors induces several immune-related adverse events. Camrelizumab-related isolate abducens neuritis is rare. Case presentation: We report on a 67-year-old man with esophageal cancer who presented with acute-onset isolated right abducens cranial nerve palsy after ten cycles of Camrelizumab treatment. Magnetic resonance imaging examination revealed thickening and post-contrast enhancement at the cisternal segment of the right abducens nerve. The diagnosis was immune-related abducens neuritis caused by Camrelizumab. We put him on oral taper corticoids (methylprednisone) for neuritis treatment without Camrelizumab suspension. One month after treatment, he recovered completely. At the last follow-up, one year after the onset of diplopia, the patient was in good condition without neurological symptom recurrence. Conclusion: Abducens neuritis is a rare immune-related adverse outcome of Camrelizumab. The present case proves the efficacy and safety of using corticoids in the treatment of abducens neuritis.

Keywords: immunotherapy; abducens neuritis; Camrelizumab; immune-related adverse events; case report

1. Introduction

Abducens nerve palsy, caused by various conditions, is a common neuro-ophthalmology outcome. Most cases are approximately 70 years old, and microvascular ischemia is the leading etiology [1]. Neuritis of the isolated abducens nerve is relatively rare. According to an early 1984 report [2], the incidence of abducens nerve palsy was 11.3/100,000 per year in the US, and only 8% of these cases were caused by inflammation.

Immune checkpoint inhibitors (ICIs) are novel immunologic agents that have revolutionized oncological practice [3]. ICIs alleviate tumor-induced T-cell inhibition, potentiate T-cell activation, and evoke anti-tumor immune attacks. Camrelizumab is a programmed death receptor 1 (PD-1) inhibitor. It received its first global approval in 2019 in China [4]. Several phase III trials [5] have demonstrated that, compared with chemotherapy, ICI treatment facilitates a significantly longer overall survival in previously treated patients with advanced esophageal cancer. Unfortunately, ICIs induced several immune-related adverse events (irAEs) due to their immune-enhanced nature. Camrelizumab has induced several immune-related adverse events (irAEs) such as pneumonitis [6], hepatitis [7], myocarditis [8] and myositis [9] in recent reports. Ophthalmic irAEs commonly manifest as uveitis (1%) and dry eye (1–24%) [10]; 83.6% of cases of ICI-related uveitis were diagnosed within six months [11].

In this study, we describe a patient with esophageal cancer who manifested isolated abducens neuritis during anti-tumor immunotherapy. Magnetic resonance imaging (MRI) can localize and characterize the lesions and is an excellent modality diagnostic tool for the abducens nerve disorder. Abducens neuritis may be an irAE of Camrelizumab.
2. Case Presentation

A 67-year-old man with esophageal cancer presented with acute-onset horizontal diplopia for two days after ten cycles of Camrelizumab treatment. The patient had no complications of ocular pain or headaches. His ocular examination was normal. A neurological examination showed isolated right abducens cranial nerve palsy. The right eye could not abduct completely, which was confirmed by the Hess screen (Figure 1). An MRI examination revealed thickening and post-contrast enhancement at the cisternal segment of the right abducens nerve (Figure 2). There was no evidence of brain tumor metastases, cerebrovascular disorder, or orbital lesions. The laboratory tests showed negative antibodies to human immunodeficiency virus (HIV)/Hepatitis C virus (HCV), rapid plasma regain (RPR), and Hepatitis B surface antigens (HBsAg).

Figure 1. (A) The right eye does not abduct when gazing in the right direction. The HESS screen test on the onset days (B), one week (C), and one month (D) after corticoid treatment. T: temporal, N: Nasal.
The patient had no history of hypertension, diabetes, heart disease, hyperlipidemia, cerebrovascular disease or autoimmune disease. He accepted radiotherapy and chemotherapy (Albumin-bound paclitaxel combined with carboplatin/Cisplatin/Nedaplatin). The chemotherapy drugs had to be changed frequently due to severe tertiary hemopenia, and the cancer was not well controlled until combined immunotherapy (Camrelizumab) was performed six months ago (Figure 5). After this, he was in good physical condition but had diplopia. The levels of the serum tumor marker were normal (CEA: 2.18 ng/mL; CYFRA211: 2.8 ng/mL; NSE: 12.33 ng/mL; Pro-Grp: 32.71 pg/mL). It was interpreted as immune-related abducens neuritis caused by Camrelizumab. The paraneoplastic syndrome-associated autoantibodies in the serum were negative. (anti-Hu, Ri, CV2, Amphiphysin, Ma1, Ma2, SOX1, Tr, Zic4, GAD65, PKCγ, Recoverin, Titin).
At the last follow-up, one year after the onset of diplopia, the patient was in good condition without tumor progression or neurological symptom recurrence.

Importantly, potentially toxic drugs were adopted before ICIs in this case. However, paclitaxel combined with platinum was administered almost fourteen cycles before the onset of abducens neuritis, which appeared abruptly and was resolved with corticosteroids, suggesting that an inflammatory rather than toxic etiology complicated ICI treatment.

Only a few case reports have reported abducens neuritis following PD-1 as possible complications (Table 1), and therefore, information on the spectrum, treatment and outcome of PD-1-induced abducens neuritis is limited.
Table 1. Cases of abducens neuritis reported with anti-PD-1 immunotherapy.

| Author/Year | Gender | Age | Tumour | Anti-PD-1 | Treatment of irAE | Outcome of irAE | Other irAE |
|-------------|--------|-----|--------|-----------|------------------|----------------|-----------|
| Vogrig, [12] 2021 | Male | 63 | Melanoma | Ipilimumab-pembrolizumab | pause of ICIs oral corticosteroids prednisone (1 mg/kg/day) | Resolved | autoimmune colitis |
| | Male | 82 | Melanoma | Nivolumab | pause of nivolumab | Resolved | facial nerve palsy |
| Zimmer, [13] 2016 | Male | 83 | Melanoma | Nivolumab | Methylprednisolone (1 mg/kg/day) | Resolved | facial nerve palsy |
| Sun, [14] 2021 | Male | 52 | Melanoma | Ipilimumab/nivolumab | Methylprednisolone; prednisone | Improved | NA |

irAE: immune-related adverse events, ICIs: immune checkpoint inhibitors. NA: not available.

3. Discussion

Cranial nerve palsy caused by neuritis is characterized by thickening and post-contrast enhancement, shown under high-resolution MRI [15]. The abducens nerve is the sixth cranial nerve. It is more frequently associated with III, IV, V and VII nerve pathology. The etiologies of acquired abducens nerve palsy include microvascular ischemia, vasculopathy, central nervous system neoplasm, multiple sclerosis, trauma, stroke, and infection [16]. However, 13–35% of cases are idiopathic [17]. Conversely, anti-tumor immunotherapy with ICIs provided inflammatory conditions that could be potential clinical courses for neuritis. In this study, we present a case of isolated abducens neuritis induced by Camrelizumab, diagnosed according to diplopia, failure of abducting, and characterized MRI images. As we know, neuritis and ischemic neuropathy are difficult to distinguish in MRI, and we cannot completely exclude the possibility of ischemia. However, the nerve thickening and post-contrast enhancement on MRI cannot be seen in ischemic lesions but in neuritis. This patient has no vasculopathic risk factors or cerebrovascular disorders, so the drug is the most likely cause.

The ICI-induced central and peripheral nerve system irAEs were found in approximately 1–3% of the patients [18]. The possible complications included limbic encephalitis, meningoencephalitis, cerebellitis, peripheral neuropathy, myasthenia gravis, and myopathy [19,20]. The ICI-induced cranial nerve irAEs were rarely described. The irAEs occur between 1 and 6 months after the initiation of the ICI. Sun et al. demonstrated that cranial nerve irAEs are less common than optic nerve but occur earlier. The irAEs occur two-thirds of cranial neuritis could be improved or resolved by corticoids, and irAEs might well be responsible for the tumor cells’ response to immunotherapy [12]. Conversely, Sun et al. [14] found that cranial neuritis responses to steroid treatment were variable. There have more propensity for poorer ocular prognosis with a higher mortality rate. Consistent with previous cases, abducens neuritis occurs commonly in skin malignant melanoma during anti-PD-1 therapy. This is because melanoma was the first and the most common indication for treatment with ICIs. Moreover, little is known regarding ICI-induced isolated cranial nerve palsy. Information on the spectrum, treatment and outcome are unavailable.

It is challenging to balance antitumor-immunotherapy and irAE treatment. Fortunately, this abducens neuritis patient recovered quickly and showed a favorable cancer prognosis. The corticoid treatment lasted for a short duration and without antitumor immunotherapy suspension. Larger-scale and longer-term studies are needed to investigate and confirm the natural course of ICI-induced isolated abducens neuritis.

4. Conclusions

Abducens neuritis is a rare irAE of Camrelizumab. The present case proves the efficacy and safety of using corticoids in the treatment of abducens neuritis.
Author Contributions: Conceptualization, Y.H. and S.T.; methodology, H.L. and S.T.; validation, Y.H., Q.S., H.L. and S.T.; formal analysis, Y.H. and Q.S.; investigation, Y.H.; resources, Y.H.; data curation, Y.H. and Q.S.; writing—original draft preparation, Y.H.; writing—review and editing, Y.H.; visualization, Y.H.; supervision, H.L. and S.T.; project administration, H.L. and S.T. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by Capital’s Funds for Health Improvement and Research (CFH) (Grant No.2022-2-20211).

Institutional Review Board Statement: This study was approved by the BFH Ethics Committee and was conducted following the latest iteration of the Declaration of Helsinki (version: 2020-P2-314-01). Participants gave written informed consent (version V1.0/2020-01-01) before inclusion in the study. All blood samples were collected as part of routine treatment for this study.

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study. Written informed consent has been obtained from the patient to publish this paper.

Data Availability Statement: All of the data in this study are in the article.

Acknowledgments: The authors are grateful to the patient for providing permission to share the medical information.

Conflicts of Interest: The authors declare no conflict of interest. Authors declare no personal circumstances or interests that may be perceived as inappropriately influencing the representation or interpretation of reported research results. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

References
1. Richards, B.W.; Jones, F.R., Jr.; Younge, B.R. Causes and prognosis in 4278 cases of paralysis of the oculomotor, trochlear, and abducens cranial nerves. Am. J. Ophthalmol. 1992, 113, 489–496. [CrossRef]
2. Moster, M.L.; Savino, P.J.; Sergott, R.C.; Bosley, T.M.; Schatz, N.J. Isolated sixth-nerve palsies in younger adults. Arch. Ophthalmol. 1984, 102, 1328–1330. [CrossRef] [PubMed]
3. Ribas, A.; Wolchok, J.D. Cancer immunotherapy using checkpoint blockade. Science 2018, 359, 1350–1355. [CrossRef] [PubMed]
4. Markham, A.; Keam, S.J. Correction to: Camrelizumab: First Global Approval. Drugs 2019, 79, 1497. [CrossRef] [PubMed]
5. Da Silva, L.L.; Aguiar, P.N., Jr.; Park, R.; Edelman Saul, E.; Haaland, B.; de Lima Lopes, G. Comparative Efficacy and Safety of Programmed Death-1 Pathway Inhibitors in Advanced Gastroesophageal Cancers: A Systematic Review and Network Meta-Analysis of Phase III Clinical Trials. Cancers 2021, 13, 2614. [CrossRef] [PubMed]
6. Li, L.; Lou, A.; Yu, J. Immune checkpoint inhibitor-related pneumonitis induced by camrelizumab: A case report and review of literature. Ann. Palliat. Med. 2021, 10, 8460–8466. [CrossRef] [PubMed]
7. Tan, Y.; Ye, Y.; Chen, L. Fatal immune-related hepatitis with intrahepatic cholestasis and pneumonia associated with camrelizumab: A case report and literature review. Open Med. 2021, 16, 553–557. [CrossRef]
8. Liang, S.; Yang, J.; Lin, Y.; Li, T.; Zhao, W.; Zhao, J.; Dong, C. Immune Myocarditis Overlapping with Myasthenia Gravis due to Anti-PD-1 Treatment for a Chordoma Patient: A Case Report and Literature Review. Front. Immunol. 2021, 12, 682262. [CrossRef]
9. Bai, J.; Li, D.; Yang, P.; Xu, K.; Wang, Y.; Li, Q.; Liu, J.; Du, W.; Zhang, F.; Feng, R. Camrelizumab-Related Myocarditis and Myositis with Myasthenia Gravis: A Case Report and Literature Review. Front. Oncol. 2021, 11, 778185. [CrossRef]
10. Dalvin, L.A.; Shields, C.L.; Orloff, M.; Sato, T.; Shields, J.A. Checkpoint Inhibitor Immune Therapy: Systemic Indications and Ophthalmic Side Effects. Retina 2018, 38, 1063–1078. [CrossRef] [PubMed]
11. Dow, E.R.; Yung, M.; Tsui, E. Immune Checkpoint Inhibitor-associated Uveitis: Review of Treatments and Outcomes. Ocul. Immunol. Inflamm. 2020, 29, 203–211. [CrossRef]
12. Vogrig, A.; Muñiz-Castrillo, S.; Joubert, B.; Picard, G.; Rogemond, V.; Skowron, F.; Egri, M.; Desestret, V.; Tilikete, C.; Psimaras, D.; et al. Cranial Nerve Disorders Associated with Immune Checkpoint Inhibitors. Neurology 2021, 96, e866–e875. [CrossRef] [PubMed]
13. Zimmer, L.; Goldinger, S.M.; Hofmann, L.; Loquai, C.; Ugurel, S.; Thomas, I.; Schmidgen, M.I.; Gutzmer, R.; Utikal, J.S.; Göppner, D.; et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur. J. Cancer 2016, 60, 210–225. [CrossRef] [PubMed]
14. Sun, M.M.; Seleme, N.; Chen, J.J.; Zeckeridou, A.; Sechi, E.; Walsh, R.D.; Beebe, J.D.; Sabbagh, O.; Mejico, L.J.; Gratton, S.; et al. Neuro-Ophthalmic Complications in Patients Treated with CTLA-4 and PD-1/PD-L1 Checkpoint Blockade. J. Neuro-Ophthalmol. Off. J. N. Am. Neuro-Ophthalmol. Soc. 2021, 41, 519–530. [CrossRef] [PubMed]
15. Park, K.A.; Min, J.H.; Oh, S.Y.; Kim, B.J. Idiopathic third and sixth cranial nerve neuritis. Jpn. J. Ophthalmol. 2019, 63, 337–343. [CrossRef] [PubMed]
16. Park, K.A.; Oh, S.Y.; Min, J.H.; Kim, B.J.; Kim, Y. Cause of acquired onset of diplopia due to isolated third, fourth, and sixth cranial nerve palsies in patients aged 20 to 50 years in Korea: A high resolution magnetic resonance imaging study. *J. Neurol. Sci.* **2019**, *407*, 116546. [CrossRef] [PubMed]

17. Peters, G.B., 3rd; Bakri, S.J.; Krohel, G.B. Cause and prognosis of nontraumatic sixth nerve palsies in young adults. *Ophthalmology* **2002**, *109*, 1925–1928. [CrossRef]

18. Dubey, D.; David, W.S.; Reynolds, K.L.; Chute, D.F.; Clement, N.F.; Cohen, J.V.; Lawrence, D.P.; Mooradian, M.J.; Sullivan, R.J.; Guidon, A.C. Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum. *Ann. Neurol.* **2020**, *87*, 659–669. [CrossRef] [PubMed]

19. Vogrig, A.; Muñiz-Castrillo, S.; Joubert, B.; Picard, G.; Rogemond, V.; Marchal, C.; Chiappa, A.M.; Chanson, E.; Skowron, F.; Leblanc, A.; et al. Central nervous system complications associated with immune checkpoint inhibitors. *J. Neurol. Neurosurg. Psychiatry* **2020**, *91*, 772–778. [CrossRef] [PubMed]

20. Touat, M.; Maisonobe, T.; Knauss, S.; Ben Hadj Salem, O.; Hervier, B.; Auré, K.; Szwebel, T.A.; Kramkimel, N.; Lethrosne, C.; Bruch, J.F.; et al. Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer. *Neurology* **2018**, *91*, e985–e994. [CrossRef] [PubMed]